Sign in

ROSG on NASDAQ

Rosetta Genomics

Logo: rosettagenomics.com5

Molecular diagnostics company

Rosetta Genomics Ltd. was a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid (microRNA) biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008.3 Its shares trade on NASDAQ under the symbol ROSG.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2000Founded1

Compare with another stock.

See how the biggest companies compare on our leaderboards

Rosetta Genomics Ltd. was a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid (microRNA) biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC); differentiate between adenocarcinoma and peritoneal mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary (CUP). Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer passed the prevalidation phase and was submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008.3

What it owns

What Rosetta Genomics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$6.4M7 Dec 31, 2016$6.1M7 Dec 31, 2015+6.1%
Accumulated depreciation$4.0M7 Dec 31, 2016$3.1M7 Dec 31, 2015+29.4%
Property and equipment, net$2.4M7 Dec 31, 2016$3.0M7 Dec 31, 2015−17.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.2M7 Dec 31, 2016$12.4M7 Dec 31, 2015−50.5%

The story

Rosetta Genomics was founded by Isaac Bentwich in 2000 to pursue commercial applications of microRNA research. The company had its IPO on March 6, 2007, and is traded on the NASDAQ. Rosetta Genomics expects the funds raised to advance its microRNA-based diagnostic and therapeutic cancer products through initial clinical validation, defined as success in identifying the specific biomarker panels via blinded tests of samples supplied

by medical institutions.

In 2016, the company was ranked #27 on the Deloitte Fast 500 North America list.

In December 2017, the American diagnostics company Genoptix agreed to acquire Rosetta Genomics for $10 million. The agreement was terminated in February 2018 after it failed to receive the required shareholder vote. A second agreement, valuing the company at $9 million, was later approved by shareholders, but the merger was not completed.

On 31 May 2018, it was announced that Rosetta Genomics filed for Chapter 7 bankruptcy.

From Wikipedia’s article on Rosetta Genomics, shared under CC BY-SA 4.0.6

Products and brands

  • microRNA

Listed on Wikidata.1

Rosetta Genomics developed several proprietary technologies that enabled the company to work with microRNAs. At the basis of these technologies are proprietary microRNA extraction protocols that include sensitive extraction of microRNAs from most body fluids, including serum, urine, saliva, with virtually no microRNA lost in the extraction process. The company also developed a microRNA extraction protocol from Formalin Fixed Paraffin

Embedded, or FFPE, samples. This allowed extraction of microRNAs from samples preserved at room temperature.

Once microRNAs are extracted, Rosetta Genomics’ technology was capable of detecting and quantifying the microRNAs using two custom designed platform technologies which utilize Quantitative Real Time PCR (or qRT-PCR) and microarrays.

The company's proprietary microarray platform covered approximately 850 human microRNAs, including approximately 180 microRNAs which were Rosetta Genomics’ proprietary microRNAs. The array's high specificity allowed discriminating homologous family members.

From Wikipedia’s article on Rosetta Genomics, shared under CC BY-SA 4.0.6

Timeline

  1. 2000Founded Founded1

SEC filer profile

How Rosetta Genomics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRosetta Genomics Ltd.2
  • CIK0001362959
  • Filer statusNon-accelerated filer2
  • Incorporated inIsrael2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address10 Plaut Street, Science Park, Pob 4059, Rehovot, L3 767062
  • Phone972-73-222-07002
  • Shares outstanding1,843,537 as of Dec 31, 20167
  • On EDGAR sinceSep 1, 20062
  • Filings412 in all: 6-K (227), SC 13G (23), CORRESP (18), SC 13G/A (17), EFFECT (16), 20-F (11), 424B5 (11), F-1/A (11)2
    All 30 form types

    UPLOAD (10), F-3 (9), 424B3 (7), CT ORDER (7), 6-K/A (6), 4 (5), F-1 (5), D (4), S-8 (4), 20-F/A (3), 424B2 (3), 424B4 (3), D/A (2), POS AM (2), 25-NSE (1), 3 (1), 8-A12B (1), CERTNAS (1), F-3/A (1), NT 20-F (1), POS EX (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) Mar 30, 2017

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Company websiteRosetta Genomics logo
  6. 6
  7. 7